🔗 Share this article

As the United States undertakes historic adjustments to its immunization guidelines, a particular individual appears in a surprising turn: Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by questioning coronavirus shots throughout the global health crisis and has concentrated on alleged deaths after COVID-19 vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Vaccine Program

Public health authorities were set to unveil radical changes to the pediatric immunization program earlier this month, bringing the US with the Danish immunization schedule, it is understood – a major change that would put the US out of step with much of the global community with no evidence for improved outcomes. The announcement has been delayed until the coming year.

Instead of Vinay Prasad, Høeg is scheduled to address the audience at the meeting. She was just designated interim head of the FDA’s drug evaluation center, the fifth individual to head the division this calendar year.

A New Direction at the Agency

This interim role may indicate a closer partnership between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a renewed priority upon dismantling previously authorized immunizations at the FDA.

The new acting director has frequently advocated for ending specific pediatric vaccine recommendations in the US in order to be more in line with the Danish model, a nation with comprehensive healthcare and a number of inhabitants about the population of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on vaccination policy – usually the purview of Prasad, chief of the FDA’s CBER – rather than drug regulation.

Doubts Over Background

Dr. Høeg has no obvious background in pharmaceutical research, oversight or management, which has been typical for former directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“She appears not to have the necessary background” for running the drug-regulation department, remarked Jonathan Howard. “She lacks experience running a scientific study. She is not versed in running a sizeable institution. She is not an expert in drug approvals.”

Former heads of CBER would “understand regulatory frameworks and the underlying principles of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the sort of resume that prior appointees who ran CBER have had.”

This division has an vast workload at the FDA, she pointed out.

“The public just pays attention on the innovative therapies, but the generic drug division authorizes a multitude of generic drugs. There is also a biosimilars division, OTC medication office and so forth, and all of those need to be looked after,” she noted. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

There is also, a significant management component to the position, which supervises more than 5,000 staff members. “It is a enormous management job, if you perform it correctly,” the former official said.

Agency Reaction and Contentious Initiatives

Regarding concerns about Dr. Høeg's qualifications and whether this selection indicates increased cooperation among agency officials on vaccines, a representative stated that the “inquiries are based on incorrect assumptions”.

“Her resume aligns with the duties of her job,” the spokesperson said, citing the months Dr. Høeg spent guiding the FDA commissioner on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg inherits the commissioner’s new fast-track approval initiative, a controversial expedited therapy clearance system that apparently troubled her former heads. “By what process are these drugs being chosen for this fast-track system? Who is making the calls?” Howard asked. “There is a lot of confidentiality happening at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration appears to be shifting towards laxer regulations of pharmaceuticals, except for shots.”

Public History on Immunizations

Regarding immunizations, Høeg has a more documented, if troubling, past, some experts said. She authored a research paper using unconfirmed volunteer-provided data to determine the incidence of heart inflammation following Covid vaccination. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccinations are more dangerous than they are.

Part of her “wish list” for the current administration featured revising rules for new vaccines and ending “optional” immunizations, she remarked following the vote on a podcast. At the FDA, Dr. Høeg has reportedly floated the idea of preventing young men from receiving COVID-19 vaccines.

“She’s an complete dogmatist who commences with her preconceived notions and works backwards to fit the evidence in a very misleading, untruthful way,” Howard said.

Consolidating Power and a “Push for Payback”

Høeg joined other skeptics, {like|